Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 24, 20 December 2023
Open
Access | Article
CRISPR/Cas9 gene editing: A promising approach towards Huntington’s Disease
* Author to whom correspondence should be addressed.
Abstract
Huntington's Disease (HD) is an incurable neurodegenerative condition marked by the gradual decline of motor abilities, cognitive capabilities, and emotional stability. It results from a mutation in the Huntingtin gene (HTT), which triggers the generation of a harmful variant of the Huntingtin protein known as mutant Huntingtin (mHTT). Despite significant advancements in understanding the disease's molecular basis, effective treatments to halt or reverse its progression remain elusive. Over the past few years, the groundbreaking genetic modification technique called Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) has risen as a hopeful tool in the realm of genetic investigation and treatment. CRISPR has the potential to precisely target and modify specific genes, offering new possibilities for the treatment of Huntington's Disease. This paper aims to provide an overview of Huntington's Disease, the CRISPR technology, and its potential applications in addressing the underlying genetic causes of HD. By exploring the fundamental aspects of both HD and CRISPR, this paper hopes to provide a clearer picture to the therapeutic potential of CRISPR in mitigating the effects of this neurodegenerative disorder.
Keywords
CRISPR Cas9, Huntington’s Disease, gene editing, neurodegenerative disorder
References
1. Walker, F. O. (2007). Huntington’s disease. The Lancet, 369(9557), 218–228. https://doi.org/10. 1016/s0140-6736(07)60111-1
2. Roos, R. A. (2010). Huntington’s disease: a clinical review. Orphanet Journal of Rare Diseases, 5(1). https://doi.org/10.1186/1750-1172-5-40
3. Adli, M. (2018). The CRISPR tool kit for genome editing and beyond. Nature Communications, 9(1). https://doi.org/10.1038/s41467-018-04252-2
4. Baumann, M. (2016). CRISPR/Cas9 genome editing – new and old ethical issues arising from a revolutionary technology. NanoEthics, 10(2), 139–159. https://doi.org/10.1007/s11569-016-0259-0
5. Gostimskaya, I. (2022). CRISPR–Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing. Biochemistry (Moscow), 87(8), 777–788. https://doi.org/10. 1134/ s0006297922080090
6. Gupta, D., Bhattacharjee, O., Mandal, D., Sen, M. K., Dey, D., Dasgupta, A., Kazi, T. A., Gupta, R., Sinharoy, S., Acharya, K., Chattopadhyay, D., Ravichandiran, V., Roy, S., & Ghosh, D. (2019). CRISPR-Cas9 system: A new-fangled dawn in gene editing. Life Sciences, 232, 116636. https://doi.org/10.1016/j.lfs.2019.116636
7. Vachey, G., & Déglon, N. (2018). CRISPR/Cas9-Mediated Genome Editing for Huntington’s Disease. Methods in Molecular Biology (Clifton, N.J.), 1780, 463–481. https://doi.org/10. 1007/978-1-4939-7825-0_21
8. Boudreau, R. L., McBride, J. L., Martins, I., Shen, S., Xing, Y., Carter, B. J., & Davidson, B. L. (2009). Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington’s Disease Mice. Molecular Therapy: The Journal of the American Society of Gene Therapy, 17(6), 1053–1063. https://doi.org/10.1038/mt.2009.17
9. Drouet, V., Ruiz, M., Zala, D., Feyeux, M., Auregan, G., Cambon, K., Troquier, L., Carpentier, J., Aubert, S., Merienne, N., Bourgois-Rocha, F., Hassig, R., Rey, M., Dufour, N., Saudou, F., Perrier, A. L., Hantraye, P., & Déglon, N. (2014). Allele-Specific Silencing of Mutant Huntingtin in Rodent Brain and Human Stem Cells. PLoS ONE, 9(6), e99341. https://doi.org/10.1371/journal.pone.0099341
10. Lee, J.M., Gillis, T., Mysore, J. S., Ramos, E. M., Myers, R. H., Hayden, M. R., Morrison, P. J., Nance, M., Ross, C. A., Margolis, R. L., Squitieri, F., Griguoli, A., Di Donato, S., Gomez-Tortosa, E., Ayuso, C., Suchowersky, O., Trent, R. J., McCusker, E., Novelletto, A., & Frontali, M. (2012). Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. American Journal of Human Genetics, 90(3), 434–444. https://doi.org/10.1016/ j.ajhg.2012.01.005
11. Bolukbasi, M. F., Gupta, A., Oikemus, S., Derr, A. G., Garber, M., Brodsky, M. H., Zhu, L. J., & Wolfe, S. A. (2015). DNA-binding-domain fusions enhance the targeting range and precision of Cas9. Nature Methods, 12(12), 1150–1156. https://doi.org/10.1038/nmeth.3624
12. Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., Virgin, H. W., Listgarten, J., & Root, D. E. (2016). Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nature Biotechnology, 34(2), 184–191. https://doi.org/10.1038/nbt.3437
13. Tycko, J., Myer, Vic E., & Hsu, Patrick D. (2016). Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity. Molecular Cell, 63(3), 355–370. https://doi.org/10.1016/j. molcel.2016.07.004
14. Doench, J. G., Hartenian, E., Graham, D. B., Tothova, Z., Hegde, M., Smith, I., Sullender, M., Ebert, B. L., Xavier, R. J., & Root, D. E. (2014). Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation. Nature Biotechnology, 32(12), 1262–1267. https://doi.org/10.1038/nbt.3026
15. Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014). Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nature Biotechnology, 32(3), 279–284. https://doi.org/10.1038/nbt.2808
16. Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013). RNA-Guided Human Genome Engineering via Cas9. Science, 339(6121), 823–826. https://doi.org/10.1126/science.1232033
17. Monteys, A. M., Ebanks, S. A., Keiser, M. S., & Davidson, B. L. (2017). CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo. Molecular Therapy, 25(1), 12–23. https://doi.org/10.1016/j.ymthe.2016.11.010
18. Kabadi, A. M., Ousterout, D. G., Hilton, I. B., & Gersbach, C. A. (2014). Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Research, 42(19), e147–e147. https://doi.org/10.1093/nar/gku749
19. Liu, J., & Shui, S. (2016). Delivery methods for site-specific nucleases: Achieving the full potential of therapeutic gene editing. Journal of Controlled Release, 244, 83–97. https://doi.org/10.1016/j.jconrel.2016.11.014
20. Wang, L., Li, F., Dang, L., Liang, C., Wang, C., He, B., Liu, J., Li, D., Wu, X., Xu, X., Lu, A., & Zhang, G. (2016). In Vivo Delivery Systems for Therapeutic Genome Editing. International Journal of Molecular Sciences, 17(5), 626. https://doi.org/10.3390/ijms17050626
21. Ran, F. A. (2017). Adaptation of CRISPR nucleases for eukaryotic applications. Analytical Biochemistry, 532, 90–94. https://doi.org/10.1016/j.ab.2016.10.018
22. Yang, S., Chang, R., Yang, H., Zhao, T., Hong, Y., Kong, H. E., Sun, X., Qin, Z., Jin, P., Li, S., & Li, X.-J. (2017). CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease. Journal of Clinical Investigation, 127(7), 2719–2724. https://doi.org/10.1172/jci92087
23. Smith, C., Gore, A., Yan, W., Abalde-Atristain, L., Li, Z., He, C., Wang, Y., Brodsky, Robert A., Zhang, K., Cheng, L., & Ye, Z. (2014). Whole-Genome Sequencing Analysis Reveals High
24. Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., & Zhang, F. (2015). Rationally engineered Cas9 nucleases with improved specificity. Science, 351(6268), 84–88. https://doi.org/10.1126/science.aad5227
25. Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., Aryee, M. J., & Joung, J. K. (2014). GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nature Biotechnology, 33(2), 187–197. https://doi.org/10.1038/nbt.3117
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-221-3
- ISBN (Online)
- 978-1-83558-222-0
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/24/20231089
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited